C Festuccia

Summary

Affiliation: University of L'Aquila
Country: Italy

Publications

  1. ncbi request reprint Culture conditions modulate cell phenotype and cause selection of subpopulations in PC3 prostate cancer cell line
    C Festuccia
    Department of Experimental Medicine, Medical School, University of L Aquila, 67100 L Aquila, Italy
    Anticancer Res 20:4367-71. 2000
  2. ncbi request reprint Osteopontin enhances the cell proliferation induced by the epidermal growth factor in human prostate cancer cells
    Adriano Angelucci
    Department of Experimental Medicine, University of L Aquila, Medical School, Coppito 2, L Aquila, Italy
    Prostate 59:157-66. 2004
  3. doi request reprint Akt down-modulation induces apoptosis of human prostate cancer cells and synergizes with EGFR tyrosine kinase inhibitors
    Claudio Festuccia
    Departments of Experimental Medicine, University of L Aquila, L Aquila, Italy
    Prostate 68:965-74. 2008
  4. ncbi request reprint Effects of 5 alpha reductase inhibitors on androgen-dependent human prostatic carcinoma cells
    Claudio Festuccia
    Prostate Biology Laboratory Department of Experimental Medicine, University of L Aquila Science and Technology School, Via Vetoio Coppito 2, 67100 L Aquila, Italy
    J Cancer Res Clin Oncol 131:243-54. 2005
  5. ncbi request reprint Gefitinib and bicalutamide show synergistic effects in primary cultures of prostate cancer derived from androgen-dependent naive patients
    Claudio Festuccia
    Department of Experimental Medicine, University of L Aquila, 67100 L Aquila, Italy
    Oncol Rep 18:1321-7. 2007
  6. ncbi request reprint Additive antitumor effects of the epidermal growth factor receptor tyrosine kinase inhibitor, gefitinib (Iressa), and the nonsteroidal antiandrogen, bicalutamide (Casodex), in prostate cancer cells in vitro
    Claudio Festuccia
    Department of Experimental Medicine, University of L Aquila, L Aquila, Italy
    Int J Cancer 115:630-40. 2005
  7. ncbi request reprint Epithelial and prostatic marker expression in short-term primary cultures of human prostate tissue samples
    Claudio Festuccia
    Department of Experimental Medicine, University of L Aquila Medical School, 67100 L Aquila, Italy
    Int J Oncol 26:1353-62. 2005
  8. ncbi request reprint Epidermal growth factor modulates prostate cancer cell invasiveness regulating urokinase-type plasminogen activator activity. EGF-receptor inhibition may prevent tumor cell dissemination
    Claudio Festuccia
    Department of Experimental Medicine, L Aquila, Italy
    Thromb Haemost 93:964-75. 2005
  9. ncbi request reprint Molecular aspects of gefitinib antiproliferative and pro-apoptotic effects in PTEN-positive and PTEN-negative prostate cancer cell lines
    C Festuccia
    Department of Experimental Medicine, University of L Aquilla, Italy
    Endocr Relat Cancer 12:983-98. 2005
  10. ncbi request reprint Uncoupling of the epidermal growth factor receptor from downstream signal transduction molecules guides the acquired resistance to gefitinib in prostate cancer cells
    Claudio Festuccia
    Department of Experimental Medicine, University of L Aquila, 67100 L Aquila, Italy
    Oncol Rep 18:503-11. 2007

Collaborators

Detail Information

Publications51

  1. ncbi request reprint Culture conditions modulate cell phenotype and cause selection of subpopulations in PC3 prostate cancer cell line
    C Festuccia
    Department of Experimental Medicine, Medical School, University of L Aquila, 67100 L Aquila, Italy
    Anticancer Res 20:4367-71. 2000
    ..However, this heterogeneity may represent a good model in the study of tumor progression...
  2. ncbi request reprint Osteopontin enhances the cell proliferation induced by the epidermal growth factor in human prostate cancer cells
    Adriano Angelucci
    Department of Experimental Medicine, University of L Aquila, Medical School, Coppito 2, L Aquila, Italy
    Prostate 59:157-66. 2004
    ..The aim of this study was to elucidate some mechanisms by which stroma controls tumor progression...
  3. doi request reprint Akt down-modulation induces apoptosis of human prostate cancer cells and synergizes with EGFR tyrosine kinase inhibitors
    Claudio Festuccia
    Departments of Experimental Medicine, University of L Aquila, L Aquila, Italy
    Prostate 68:965-74. 2008
    ..PTEN is a well-characterized tumor suppressor that negatively regulates cell growth and survival through the modulation of PI3K/Akt pathway...
  4. ncbi request reprint Effects of 5 alpha reductase inhibitors on androgen-dependent human prostatic carcinoma cells
    Claudio Festuccia
    Prostate Biology Laboratory Department of Experimental Medicine, University of L Aquila Science and Technology School, Via Vetoio Coppito 2, 67100 L Aquila, Italy
    J Cancer Res Clin Oncol 131:243-54. 2005
    ....
  5. ncbi request reprint Gefitinib and bicalutamide show synergistic effects in primary cultures of prostate cancer derived from androgen-dependent naive patients
    Claudio Festuccia
    Department of Experimental Medicine, University of L Aquila, 67100 L Aquila, Italy
    Oncol Rep 18:1321-7. 2007
    ....
  6. ncbi request reprint Additive antitumor effects of the epidermal growth factor receptor tyrosine kinase inhibitor, gefitinib (Iressa), and the nonsteroidal antiandrogen, bicalutamide (Casodex), in prostate cancer cells in vitro
    Claudio Festuccia
    Department of Experimental Medicine, University of L Aquila, L Aquila, Italy
    Int J Cancer 115:630-40. 2005
    ..This causes a significant delay in the onset of EGFR-driven androgen independence...
  7. ncbi request reprint Epithelial and prostatic marker expression in short-term primary cultures of human prostate tissue samples
    Claudio Festuccia
    Department of Experimental Medicine, University of L Aquila Medical School, 67100 L Aquila, Italy
    Int J Oncol 26:1353-62. 2005
    ..The primary cultures derived from prostatic tissues can be an extremely important method to study genetic and molecular changes involved in PCa progression...
  8. ncbi request reprint Epidermal growth factor modulates prostate cancer cell invasiveness regulating urokinase-type plasminogen activator activity. EGF-receptor inhibition may prevent tumor cell dissemination
    Claudio Festuccia
    Department of Experimental Medicine, L Aquila, Italy
    Thromb Haemost 93:964-75. 2005
    ....
  9. ncbi request reprint Molecular aspects of gefitinib antiproliferative and pro-apoptotic effects in PTEN-positive and PTEN-negative prostate cancer cell lines
    C Festuccia
    Department of Experimental Medicine, University of L Aquilla, Italy
    Endocr Relat Cancer 12:983-98. 2005
    ....
  10. ncbi request reprint Uncoupling of the epidermal growth factor receptor from downstream signal transduction molecules guides the acquired resistance to gefitinib in prostate cancer cells
    Claudio Festuccia
    Department of Experimental Medicine, University of L Aquila, 67100 L Aquila, Italy
    Oncol Rep 18:503-11. 2007
    ..Therefore, the ability of tumor cells to maintain high ERK activity under EGFR inhibition could represent a potential mechanism of the resistance to gefitinib...
  11. ncbi request reprint In vitro and in vivo effects of bicalutamide on the expression of TrkA and P75 neurotrophin receptors in prostate carcinoma
    Claudio Festuccia
    Department of Experimental Medicine, University of L Aquila, L Aquila, Italy
    Prostate 67:1255-64. 2007
    ..Neurotrophine tyrosine kinase receptors (NTR) are expressed in prostate carcinoma (PCa), and their distribution seems to be related to disease malignancy...
  12. ncbi request reprint Tyrosine kinase inhibitor CEP-701 blocks the NTRK1/NGF receptor and limits the invasive capability of prostate cancer cells in vitro
    Claudio Festuccia
    Department of Experimental Medicine, University of L Aquila, I 67100 L Aquila, Italy
    Int J Oncol 30:193-200. 2007
    ..CEP-701 is a trademark of Cephalon Inc., West Chester, PA, USA...
  13. ncbi request reprint Downmodulation of dimethyl transferase activity enhances tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in prostate cancer cells
    Claudio Festuccia
    Department of Experimental Medicine, University of L Aquila, I 67100 L Aquila, Italy
    Int J Oncol 33:381-8. 2008
    ....
  14. ncbi request reprint Osteoblast-derived TGF-beta1 modulates matrix degrading protease expression and activity in prostate cancer cells
    C Festuccia
    Department of Experimental Medicine, Medical School, University of L Aquila, Italy
    Int J Cancer 85:407-15. 2000
    ....
  15. ncbi request reprint Osteoblast conditioned media contain TGF-beta1 and modulate the migration of prostate tumor cells and their interactions with extracellular matrix components
    C Festuccia
    Department of Experimental Medicine, Medical School, University of L Aquila, Italy
    Int J Cancer 81:395-403. 1999
    ..Given the widespread tissue distribution of TGF-beta1, and the high levels present in the bone, this cytokine may be an important autocrine-paracrine modulator of the bone invasive phenotype in vivo...
  16. doi request reprint Her2 crosstalks with TrkA in a subset of prostate cancer cells: rationale for a guided dual treatment
    Claudio Festuccia
    Department of Experimental Medicine, Chair of General Pathology, University of L Aquila, Italy
    Prostate 69:337-45. 2009
    ..It has been demonstrated that the simultaneous high expression of p185(HER2) and TrkA might confer a proliferative advantage to PCa cells...
  17. ncbi request reprint Bombesin-dependent pro-MMP-9 activation in prostatic cancer cells requires beta1 integrin engagement
    Claudio Festuccia
    Department of Experimental Medicine, University of L Aquila, Italy
    Exp Cell Res 280:1-11. 2002
    ..This finding supports the idea that cellular responses to growth factors may be driven by cell-matrix interactions and stresses the role of neuroendocrine factors in prostate carcinoma progression...
  18. doi request reprint Azacitidine improves antitumor effects of docetaxel and cisplatin in aggressive prostate cancer models
    Claudio Festuccia
    Department of Experimental Medicine, Chair of General Pathology, University of L Aquila, 67100 L Aquila, Italy
    Endocr Relat Cancer 16:401-13. 2009
    ..Our results provide a rationale for clinical trials on combination treatments with azacitidine in patients with hormone-refractory and chemoresistant prostate tumors...
  19. ncbi request reprint Bicalutamide increases phospho-Akt levels through Her2 in patients with prostate cancer
    Claudio Festuccia
    Department of Experimental Medicine, University of L Aquila, 67100 L Aquila, Italy
    Endocr Relat Cancer 14:601-11. 2007
    ....
  20. ncbi request reprint Osteoblasts modulate secretion of urokinase-type plasminogen activator (uPA) and matrix metalloproteinase-9 (MMP-9) in human prostate cancer cells promoting migration and matrigel invasion
    C Festuccia
    Department of Experimental Medicine, Medical School, University of L Aquila, Italy
    Oncol Res 11:17-31. 1999
    ....
  21. doi request reprint Chronic azacitidine treatment results in differentiating effects, sensitizes against bicalutamide in androgen-independent prostate cancer cells
    Giovanni Luca Gravina
    Department of Experimental Medicine, University of L Aquila, L Aquila, Italy
    Prostate 68:793-801. 2008
    ..We also studied whether epigenetically reactivated AR is a target for bicalutamide therapy...
  22. doi request reprint Bicalutamide demonstrates biologic effectiveness in prostate cancer cell lines and tumor primary cultures irrespective of Her2/neu expression levels
    Giovanni Luca Gravina
    Department of Experimental Medicine, University of L Aquila, San Salvatore Hospital, Italy
    Urology 74:452-7. 2009
    ..To evaluate the role of Her2/neu as a molecular marker predictive of the treatment response to bicalutamide in prostate cancer (PCa)...
  23. doi request reprint Biomolecular characterization of human glioblastoma cells in primary cultures: differentiating and antiangiogenic effects of natural and synthetic PPARgamma agonists
    E Benedetti
    Department of Basic and Applied Biology, University of L Aquila, L Aquila, Italy
    J Cell Physiol 217:93-102. 2008
    ..We provide evidence that PPARgamma agonists may interfere with glioblastoma growth and malignancy and might be taken in account as novel antitumoral drugs...
  24. doi request reprint 5-Azacitidine restores and amplifies the bicalutamide response on preclinical models of androgen receptor expressing or deficient prostate tumors
    Giovanni Luca Gravina
    Division of Radiotherapy, Department of Experimental Medicine, University of L Aquila, L Aquila, Italy
    Prostate 70:1166-78. 2010
    ..This study tested the hypothesis that 5-Aza may restore and enhance the responsiveness of HRPC cells to anti-hormonal therapy on Androgen receptor (AR) expressing (22rv1) and AR-deficient (PC3) cells...
  25. ncbi request reprint Pyrrolopyrimidine c-Src inhibitors reduce growth, adhesion, motility and invasion of prostate cancer cells in vitro
    I Recchia
    Department of Experimental Medicine, Via Vetoio, Coppito 2, 67100 L Aquila, Italy
    Eur J Cancer 39:1927-35. 2003
    ..Collectively, these data demonstrate that the pyrrolopyrimidine-derived c-Src inhibitors significantly reduced PC3 cell activities associated with their malignant phenotype...
  26. ncbi request reprint Suppression of EGF-R signaling reduces the incidence of prostate cancer metastasis in nude mice
    Adriano Angelucci
    Department of Surgery, University of L Aquila Via Vetoio, Coppito 2, 67100 L Aquila, Italy
    Endocr Relat Cancer 13:197-210. 2006
    ..In conclusion, our data suggest that the use of gefitinib as a therapeutic agent may be indicated in the control of PCa spreading to bone...
  27. ncbi request reprint Prostate cancer cell proliferation is strongly reduced by the epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 in vitro on human cell lines and primary cultures
    Carlo Vicentini
    Prostate Biology Laboratory, Department of Surgery, University of L Aquila, Medical School, Coppito 2, 67100, L Aquila, Italy
    J Cancer Res Clin Oncol 129:165-74. 2003
    ....
  28. ncbi request reprint Establishment and characterization of a human prostatic carcinoma cell strain obtained from exfoliated tumor cells after prostatic massage
    M Bologna
    Department of Experimental Medicine, University of L'Aquila Medical School, Italy
    Tumori 77:70-5. 1991
    ....
  29. ncbi request reprint Surgical and biologic outcomes after neoadjuvant bicalutamide treatment in prostate cancer
    Giovanni Luca Gravina
    Department of Urology, University of L Aquila, Italy
    Urology 70:728-33. 2007
    ....
  30. ncbi request reprint Osteoblast-conditioned media stimulate membrane vesicle shedding in prostate cancer cells
    Danilo Millimaggi
    Department of Experimental Medicine, University of L Aquila, 67100 L Aquila, Italy
    Int J Oncol 28:909-14. 2006
    ..Collectively, these findings indicate that osteoblasts produce factor/s able to modify the invasive capability of prostate cancer cells, increasing the amount of shed vesicles and of their associated lytic enzymes...
  31. doi request reprint Vitamin D protects human endothelial cells from H₂O₂ oxidant injury through the Mek/Erk-Sirt1 axis activation
    Lorella Polidoro
    Department of Internal Medicine and Public Health, University of L Aquila, L Aquila, Italy
    J Cardiovasc Transl Res 6:221-31. 2013
    ..SirT-1 inhibition by Sirtinol reverted the vitamin D anti-oxidant effects. Thus, vitamin D significantly reduced the endothelial malfunction and damage caused by oxidative stress, through the activation of MEKs/ERKs/SirT-1 axis...
  32. ncbi request reprint PPARbeta agonists trigger neuronal differentiation in the human neuroblastoma cell line SH-SY5Y
    S Di Loreto
    ITOI, CNR, L Aquila, Italy
    J Cell Physiol 211:837-47. 2007
    ....
  33. ncbi request reprint The impact of conventional or hypofractionated radiotherapy on voice quality and oncological outcome in patients with early glottic cancer
    L Di Nicola
    Department of Experimental Medicine, Division of Radiotherapy, Radiobiology Laboratory, University of L Aquila, L Aquila, Italy
    Oncol Rep 24:1383-8. 2010
    ..Thus, we provide clinical evidence to justify trends already emerging toward hypofractionated regimens in early glottic cancer...
  34. ncbi request reprint Osteopontin modulates prostate carcinoma invasive capacity through RGD-dependent upregulation of plasminogen activators
    Adriano Angelucci
    Department of Experimental Medicine, University of L Aquila, Italy
    Biol Chem 383:229-34. 2002
    ..Our findings suggest that osteopontin may confer selective malignant potential to prostate cancer cells through the enhancement of their invasive and proteolytic capability...
  35. doi request reprint Subjective and objective measures of late genitourinary morbidity following hypofractionated radiotherapy in men with prostate cancer
    V Tombolini
    Department of Experimental Medicine, Division of Radiotherapy, University of L Aquila, L Aquila, Italy
    Prostate Cancer Prostatic Dis 13:34-8. 2010
    ..Our study seems to suggest that our hypofractionated radiotherapy schedule for the treatment of prostate cancer is safe in terms of late urinary morbidity. Further study will be required to confirm our results...
  36. ncbi request reprint Evaluation of metastatic potential in prostate carcinoma: an in vivo model
    Adriano Angelucci
    Department of Basic and Applied Biology, University of L Aquila, Medical School and Science and Technology School, Coppito 2, I 67100 L Aquila, Italy
    Int J Oncol 25:1713-20. 2004
    ..This study demonstrates that heart injection of prostate cancer cells in nude mice may represent a good experimental model to investigate the pathophysiology of bone and bone marrow metastases in vivo...
  37. doi request reprint Effects of dutasteride on prostate carcinoma primary cultures: a comparative study with finasteride and MK386
    Claudio Festuccia
    Department of Experimental Medicine, University of L Aquila, L Aquila, Italy
    J Urol 180:367-72. 2008
    ....
  38. ncbi request reprint Matrix-degrading proteinases are shed in membrane vesicles by ovarian cancer cells in vivo and in vitro
    V Dolo
    Dipartimento di Medicina Sperimentale, Universita dell Aquila, Italy
    Clin Exp Metastasis 17:131-40. 1999
    ..Taken together, our results point to a possible role of shed vesicles, both in vivo and in vitro, in proteolysis that mediates invasion and spread of ovarian epithelial carcinoma cells...
  39. ncbi request reprint Ultrastructural and phenotypic characterization of CABA I, a new human ovarian cancer cell line
    V Dolo
    Dipartimento di Medicina Sperimentale, Universita di L Aquila, Italy
    Oncol Res 9:129-38. 1997
    ....
  40. ncbi request reprint Female reproductive dysfunction during ageing: role of methylglyoxal in the formation of advanced glycation endproducts in ovaries of reproductively-aged mice
    C Tatone
    Department of Health Sciences, University of L Aquila, Via Vetoio, L Aquila, Italy
    J Biol Regul Homeost Agents 24:63-72. 2010
    ..In conclusion, the present results show that impaired MG detoxification causing relevant damage to the ovarian proteome might be one of the mechanisms underlying reproductive ageing and/or ageing-like ovarian diseases...
  41. ncbi request reprint Epigenetic modulation of PTEN expression during antiandrogenic therapies in human prostate cancer
    Giovanni Luca Gravina
    Department of Experimental Medicine, Division of Radiotherapy, University of L Aquila, 67100 L Aquila, Italy
    Int J Oncol 35:1133-9. 2009
    ....
  42. doi request reprint Ozarelix, a fourth generation GnRH antagonist, induces apoptosis in hormone refractory androgen receptor negative prostate cancer cells modulating expression and activity of death receptors
    Claudio Festuccia
    Radiobiology Laboratory, Department of Experimental Medicine, University of L Aquila, L Aquila, Italy
    Prostate 70:1340-9. 2010
    ..This study explored the in vitro effects on DU145 and PC3 cell lines, two models of androgen-independent prostate cancer, of a fourth generation GnRH antagonist (Ozarelix)...
  43. ncbi request reprint Pyrazolo[3,4-d]pyrimidines c-Src inhibitors reduce epidermal growth factor-induced migration in prostate cancer cells
    Adriano Angelucci
    Dip Scienze Chirurgiche, University of L Aquila, 67100 L Aquila, Italy
    Eur J Cancer 42:2838-45. 2006
    ..Our data suggest a promising role for pyrazolo[3,4-d]pyrimidines c-Src inhibitors in the control of a highly invasive tumour phenotype...
  44. doi request reprint Effects of EGFR tyrosine kinase inhibitor erlotinib in prostate cancer cells in vitro
    Claudio Festuccia
    Laboratory of Radiobiology, Department of Experimental Medicine, University of L Aquila, L Aquila, Italy
    Prostate 69:1529-37. 2009
    ..Why, differently to other tumors, have EGFR inhibitors been so ineffective in human prostate cancer? This is the question that we have set in this report...
  45. ncbi request reprint PPARgamma-dependent effects of conjugated linoleic acid on the human glioblastoma cell line (ADF)
    Annamaria Cimini
    Department of Basic and Applied Biology, University of L Aquila, L Aquila, Italy
    Int J Cancer 117:923-33. 2005
    ..Moreover, the gamma-agonist, once experimented and validated on man, may represent a useful coadjuvant in glioblastoma therapy and in the prevention of recurrences...
  46. doi request reprint Hypofractionated radical radiotherapy in elderly patients with medically inoperable stage I-II non-small-cell lung cancer
    Pierluigi Bonfili
    Department of Experimental Medicine, Division of Radiation Oncology, S Salvatore Hospital, L Aquila, University of L Aquila, Medical School, Medical School Via Vetoio, Coppito 11 A, 67100 L Aquila, Italy
    Lung Cancer 67:81-5. 2010
    ..Although the performances of our regimen were lower than the ones achieved by SBRT, our therapeutic option may offer a lower incidence of complications against a satisfactory local tumor control...
  47. ncbi request reprint Characterization of prostate cancer DU145 cells expressing the recombinant androgen receptor
    Eugenia Scaccianoce
    Centre for Endocrinological Oncology, Institute of Endocrinology, University of Milan, Italy
    Oncol Res 14:101-12. 2003
    ..Some of the effects described may thus be mediated by a ligand-independent activation of AR in DU145 cells...
  48. ncbi request reprint Long-term presence of androgens and anti-androgens modulate EGF-receptor expression and MAP-kinase phosphorylation in androgen receptor-prostate positive cancer cells
    Giovanni Luca Gravina
    Division of Urology, Department of Surgery, University of L Aquila, L Aquila, Italy
    Int J Oncol 25:97-104. 2004
    ..Up-regulation of EGFR in response to long-term HF treatment could represent an attempt to rescue cell growth through a compensatory survival pathway...
  49. ncbi request reprint Bicalutamide dose-dependently inhibits proliferation in human prostatic carcinoma cell lines and primary cultures
    Carlo Vicentini
    Chair of Urology, Department of Surgery, University of L Aquila Medical School, Via Vetoio, Coppito 2, 67100 L Aquila, Italy
    Anticancer Res 22:2917-22. 2002
    ..We tested the efficacy of BCLT in inhibiting proliferation of human PCa cell lines and of primary cultures from biopsies of PCa patients...
  50. ncbi request reprint Detection of telomerase activity in prostate massage samples improves differentiating prostate cancer from benign prostatic hyperplasia
    Carlo Vicentini
    Department of Surgery, University of L Aquila, Italy
    J Cancer Res Clin Oncol 130:217-21. 2004
    ....
  51. ncbi request reprint Inhibition of interleukin-8 (CXCL8/IL-8) responses by repertaxin, a new inhibitor of the chemokine receptors CXCR1 and CXCR2
    Federica Casilli
    Dompé S p A Research Center, L Aquila, Italy
    Biochem Pharmacol 69:385-94. 2005
    ..These data suggest that repertaxin is a potent and specific inhibitor of a wide range of CXCL8-mediated activities related to leukocyte recruitment and functional activation in inflammatory sites...